Tìm theo
Aleglitazar
Thuốc Gốc
Small Molecule
CAS: 475479-34-6
CTHH: C24H23NO5S
PTK: 437.508
Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes. In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects and toxicity.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C24H23NO5S
Phân tử khối
437.508
Monoisotopic mass
437.129693541
InChI
InChI=1/C24H23NO5S/c1-15-19(25-23(30-15)16-6-4-3-5-7-16)10-12-29-20-9-8-17(14-21(28-2)24(26)27)22-18(20)11-13-31-22/h3-9,11,13,21H,10,12,14H2,1-2H3,(H,26,27)/t21-/s2
InChI Key
InChIKey=DAYKLWSKQJBGCS-RNZRUAGMNA-N
IUPAC Name
(2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid
Traditional IUPAC Name
aleglitazar
SMILES
CO[C@@H](CC1=CC=C(OCCC2=C(C)OC(=N2)C2=CC=CC=C2)C2=C1SC=C2)C(O)=O
Độ hòa tan
7.97e-03 g/l
logP
4.76
logS
-4.7
pKa (strongest acidic)
4.3
pKa (Strongest Basic)
0.93
PSA
81.79 Å2
Refractivity
127.76 m3·mol-1
Polarizability
46.4 Å3
Rotatable Bond Count
9
H Bond Acceptor Count
5
H Bond Donor Count
1
Physiological Charge
-1
Number of Rings
4
Bioavailability
1
Rule of Five
true
Ghose Filter
true
MDDR-Like Rule
true
Cơ Chế Tác Dụng : Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes. In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects and toxicity. Aleglitazar was rationally designed to be an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes. Agonistic action at PPARα controls lipid levels, which improves dyslipidemia, and agonistic action at PPARγ controls glucose levels, which improves insulin sensitivity in diabetes.
Chỉ Định : Investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity.
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB08915
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D08845
Wikipedia
http://en.wikipedia.org/wiki/Aleglitazar
... loading
... loading